Antibody Mimetics/Scaffolds TRIZ Cases

Specific DR5 domain mutations improve TRAIL binding and apoptosis blocking, enabling lower-dose protection against myocardial and cerebral infarction.

Circularly permuted HaloTag fusion sensors irreversibly label analyte-driven events, enabling integrated in vivo readout across whole organs.

A35-M1 chimeric antigen fusion targets both IMV and EEV particles, enabling a safer recombinant Mpox subunit vaccine with scalable production.

A 12-amino-acid CAR spacer improves tumor recognition, T cell proliferation, cytokine production, and in vivo therapeutic activity.

Engineered CAR exosomes target CD19 or CD22 to penetrate solid tumors more effectively while reducing adverse effects seen with CAR-T cells.

Engineered ActRIIB-Fc variants selectively trap activins and GDFs while sparing BMP-9/10 to reduce vascular disruption in metabolic and fibrotic disease.

A GDF15-Fc fusion approach targets CMS and HFpEF by improving metabolic function, lowering heart weight, and boosting exercise capacity.

Genetically modified CD4+ helper T cells support CD8+ T-cell survival, proliferation, and sustained anti-tumor reactivity after transfer.

A mutated PD1 ectodomain in CAR-NK cells turns PD-L1 tumor suppression into an activation signal for stronger tumor cell killing.

Binding a therapeutic construct to serum albumin with an sdAb extends half-life, cutting injection frequency, side effects, and treatment burden.

Feeder-free multi-chain chimeric polypeptides activate and expand NK cells faster, avoiding purification steps while preserving cytotoxicity.

Modified variable regions and reduced FcγR binding let an antigen-binding molecule target multiple antigens without harmful T-cell cross-linking.

Mucosal delivery of an Fc-fused IL-7 protein boosts antigen-specific T cells to treat or prevent HPV disease with fewer injection burdens.

Blocking the NME7-MUC1* interaction with targeted antibodies helps suppress tumor growth and metastatic potential in cancer.

Specific glutamine motifs in antibody constant-region loops enable direct transglutaminase conjugation without deglycosylation or complex re-engineering.

Treg depletion with PD-1-targeted IL-2 and radiation helps overcome cold-tumor resistance and sustain anti-tumor immunity.

Targeting the Galectin-3 carbohydrate binding domain blocks receptor lattice signaling, reducing metastasis and boosting immune response.

By removing sialoglycans at the T cell-tumor interface, BiTE-sialidase fusions strengthen immune synapses and improve solid tumor killing.

Cell-penetrating BI-1 modulating peptides bind BI-1 to raise cytosolic calcium and trigger selective apoptosis in cancer cells.

Polypeptide ligands fused to AAV VP2 improve target-cell binding, raise transduction, and restrict biodistribution for safer gene delivery.

Conditional CLEC9A targeting localizes modified IFNα2 activity, extending exposure and limiting systemic toxicity in therapeutic protein complexes.

Peptide backbones space fluorescent dyes to limit self-quenching while preserving small label size, brightness, and tissue penetration.

Bispecific anti-TL1A and anti-TNF-α binding proteins improve response durability by blocking two inflammatory pathways in one antibody format.

A truncated non-LTR reverse transcriptase enables continuous cDNA synthesis across non-continuous templates while reducing bias and DNA degradation.

Electrical monitoring of capture rate changes in nanopore conjugates enables faster multi-analyte detection and concentration measurement in fluids.

A DEEP fusion tag improves recombinant protein expression, solubility, and purification across diverse target proteins without testing multiple tags.

Antibody-like polypeptides bind SARS-CoV-2 Spike to block host receptor interaction and inhibit viral entry for COVID-19 treatment.

Selective inhibition of GDF-15 and TGF-β ligands treats fibrosis and pulmonary arterial hypertension while avoiding broad-pathway toxicity.

Blocking OPG binding to RANKL and TRAIL shifts PAH treatment beyond transient vasodilation to reduce vascular remodeling and right heart failure.

By coupling voltage-sensitive proteins with dye-capturing tags, this case improves neuron-targeted voltage imaging brightness and photostability.

Engineered CD25 variants boost IL-2 sensitivity in targeted cells, enabling lower doses and reducing systemic toxicity and off-target activation.

Non-peptide rotatable linkers let hybrid immunoglobulins bind symmetric targets cooperatively, sharply lowering dose needs and cost.

Self-assembling Z33 amphiphiles capture IgG with protein A-like affinity, then enable centrifugation-based purification without costly chromatography columns.

A GIPR-binding antibody fused with a GLP-1 agonist counters rapid GLP-1 degradation while improving glucose control, weight loss, and insulin sensitivity.

Site-specific IL-34 variants tune CSF-1R, PTP-ζ, and CD138 signaling to improve transplant tolerance and limit immune rejection.

By blocking IL-31 binding to canine IL-31RA, caninized antibodies reduce itch and skin inflammation in canine atopic dermatitis.

Prime-boost HIV envelope compositions target bnAb precursors and UCAs to drive cross-reactive neutralizing antibodies with broader HIV-1 coverage.

Labeled MHC:peptide complexes use barcode or HaloTag moieties to identify TCR binders faster and more precisely at high throughput.

Leucine zipper heterodimerization helps chimeric cytokine receptors sustain CAR T cell expansion, persistence, and antitumor activity.

ForCE-based chain exchange builds multispecific ADCs with defined payload position and stoichiometry while avoiding random coupling complexity.

Bifunctional sortilin-target binders recruit extracellular proteins into lysosomes, enabling degradation beyond cytosolic PROTAC limits.

Self-activating FRET biosensors improve kinase activity sensitivity in mammalian cells while reducing noise for inhibitor screening.

RIAD/RIDD-guided LGOX and KatG assembly supplies α-KG while removing H2O2 in situ, enabling efficient one-pot 4-HIL synthesis.

Neutralizing NBL1 with antibodies or soluble BMP2 helps protect podocytes and slow diabetic or glomerular kidney damage progression.

Specific GLP-1 mutations combined with an Fc region slow degradation and clearance, supporting longer-acting diabetes treatment with less frequent dosing.

Negative supercoiling lets Alicyclobacillus Cas9 variants edit double-stranded DNA with relaxed or no PAM requirement, expanding targetable sites.

slg-targeted diphtheria toxin fusion proteins selectively eliminate pathogenic B cells while sparing non-pathogenic cells and reducing immune deficiency.

Caninized antibodies block canine IL-31 receptor alpha to reduce pruritus and skin inflammation in atopic dermatitis.

Single-domain antibodies multimerize selected cytokine receptor pairs to activate target immune cells while limiting undesired signaling in non-target cells.

By encoding only A35R and MIR antigens, this monkeypox mRNA vaccine improves safety while preserving protective immune responses.